Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Reducing Adverse Event Risk

Posted on September 25th, 2017 by in Pharma R&D

In 2012, the U.S. Food and Drug Administration (FDA) provided draft guidance for the industry on drug interaction studies, stating that “pharmacokinetic interactions between an investigational new drug and other drugs should be defined during drug development, as part of an adequate assessment of the drug’s safety and effectiveness.” Continue reading “Reducing Adverse Event Risk” »

Focus on Nutraceuticals & Natural Products: Medical Use of Cannabis

Posted on July 5th, 2017 by in Pharma R&D

These days, there is a lot of focus on nutraceuticals and ‘natural products’, derived from nature or alternately synthesized as ‘nature-identical compounds’ and used in nutraceuticals products. Continue reading “Focus on Nutraceuticals & Natural Products: Medical Use of Cannabis” »

Women and minorities in clinical trials

Posted on September 16th, 2016 by in Pharma R&D

You are a female and/or a minority and concerned if you will respond to your medication. So you read the product label, asking yourself, “Do I see myself described as a patient in the drug testing trials?” Continue reading “Women and minorities in clinical trials” »